Abstract: A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD+ precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage.

Abstract: Compositions may be used for a variety of therapeutic applications, including treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, in particular in condition of oxidative stress, such as aging, exercise, musculo-skeletal diseases, respiratory diseases, pain syndromes, neurodegenerative diseases and metabolic diseases. The compositions can contain a combination of a combination of at least one of glycine or a functional derivative thereof, and at least one large neutral amino acid and/or cationic amino acid or precursors thereof. The compositions can be food products or nutritional supplements.

Abstract: A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD+ precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage.

Abstract: Compositions and methods can use a combination of an autophagy inducer, such as spermidine, and high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of an autophagy inducer and high protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.

Abstract: The present invention provides compounds and compositions containing reduced nicotinamide riboside for use in methods of prevention and/or treatment of cardiovascular disease and/or conditions. In one embodiment of the invention, said compounds and compositions of the invention maintain or improve cardiovascular tissue and cellular function. In another embodiment of the invention, said compounds and compositions of the invention enhance cardiovascular recovery after injury or surgery.

Abstract: A method of potentiating musculoskeletal effect of one or more anabolic amino acids in an individual in need thereof can include administering to the individual in need thereof a composition containing the one or more anabolic amino acids, the composition also containing one or more autophagy-inducing compounds in a total amount effective for the composition to be at least neutral regarding autophagy. In another aspect, a method of overcoming one or more negative effects of one or more anabolic amino acids by preventing degenerative processes related to loss of autophagy can include administering to an individual in need thereof a composition containing the one or more anabolic amino acids, the composition further containing the one or more autophagy-inducing compounds in a total amount effective for the composition to be at least neutral regarding autophagy.

Abstract: A method of potentiating musculoskeletal effect of one or more anabolic amino acids in an individual in need thereof can include administering to the individual in need thereof a composition containing the one or more anabolic amino acids, the composition also containing one or more autophagy-inducing amino acids in a total amount effective for the composition to be at least neutral regarding autophagy. In another aspect, a method of overcoming one or more negative effects of one or more anabolic amino acids by preventing degenerative processes related to loss of autophagy can include administering to an individual in need thereof a composition containing the one or more anabolic amino acids, the composition further containing the one or more autophagy-inducing amino acids in a total amount effective for the composition to be at least neutral regarding autophagy.

Abstract: Compositions and methods can use a combination of thymol and/or carvacrol, optionally with high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of thymol and/or carvacrol, optionally with protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials.

Abstract: A method of improving and/or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy-inducing compounds. In one embodiment, the one or more autophagy-inducing compounds are selected from the group consisting of thymol, carvacrol, spermidine, urolithin (e.g., Urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5? AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g. beta-hydroxybutyrate, ketone salts, or ketone ester derivatives), 4,4?-dimethoxychalcone and mixtures thereof.

Abstract: A composition can treat or prevent at least one physical state selected from the group consisting of oxidative stress, a condition associated with oxidative stress, a reduced level of glutathione, and a condition associated with a reduced level of glutathione. The composition contains an effective amount of a combination of at least one glycine or functional derivative thereof, at least one N-acetylcysteine or functional derivative thereof, and at least one nicotinamide riboside or NAD precursor. The composition can be orally administered, for example as one or more of a food product, a food for special medical purposes (FSMP), a nutritional supplement, a ready to drink formula, a dairy-based drink, a low-volume liquid supplement, powder formats for liquid reconstitution or a meal replacement beverage.

Abstract: Compositions and methods can use a combination of an autophagy inducer, such as spermidine, and high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing a combination of an autophagy inducer and high protein is administered to the individual in an amount effective to induce autophagy, for example in muscle. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.

Abstract: Compositions and methods can use high protein for induction of autophagy in an individual in need thereof. Preferably, a formulation containing protein in an amount effective to induce autophagy, for example in muscle, is administered to the individual. The formulation can concomitantly promote protein synthesis and removal of damaged cellular materials. The recipient of administration can be a critically ill patient, for example a patient in the Intensive Care Unit (ICU), and/or an ageing patient, for example an elderly individual or an individual with sarcopenia.